01 — At a Glance
The Comeback Kid That Nobody Asked For
- 52-Week High / Low₹1,870 / ₹1,154
- Q3 Revenue (Dec 2025)₹888 Cr
- Q3 PAT (Dec 2025)₹61 Cr
- Q3 EPS (Dec 2025)₹3.63
- Annualised EPS (Q3×4)₹14.52
- Book Value₹281
- Price to Book4.71x
- Dividend Yield0.00%
- Interest Coverage1.64x
- Debt Amount₹2,456 Cr
Auditor’s Opening Note: Wockhardt posted Q3 revenue of ₹888 crore (up 22% YoY), PAT of ₹61 crore with operating margin at 20%. Stock trades at 198x P/E, which sounds insane until you realize the company lost money for five consecutive years and just broke even in H1 FY25. A biotech giant is injecting ₹1,000 crore of fresh equity. US FDA just approved its first-ever novel antibiotic. The valuation is not a meme—it’s pricing in a turnaround that’s already happening. Whether it sustains is another question entirely.
02 — Introduction
The Pharma Company That Bet Everything on One Thing
Wockhardt is not boring. Never has been. A company owned by the Khorakiwala family since 1959, listed since 1987, and — until recently — a cautionary tale of how a global ambition and bad timing can turn a legacy into a penny stock that trades at ₹350 per share on your broker’s “momentum kill” list.
Here’s the problem: the global generics market is commoditised. India has ~5,000 generic manufacturers. Margins are razor-thin. Volumes matter. Scale matters. And if you don’t have either, you’re just moving pills around for 12–15% margin. Wockhardt, with ₹3,151 crore in annual revenue across 12 manufacturing plants globally, is trying to escape that treadmill.
Its escape route? Novel chemical entities (NCEs)—drugs Wockhardt invented itself, not licensed from others. Six antibiotics approved for QIDP status by the US FDA. One already filed with the FDA. One just completed Phase III trials. One approaching European approval. And management admitted in November 2024 that they’ve already invested ₹2,000 crore in this journey, with ₹1,000 crore more coming post-QIP.
That’s ₹3,000 crore spent on molecules that haven’t generated revenue yet. In a company that earned ₹109 crore in annual profit last year. Let that marinate. This isn’t a pharma company anymore. It’s a biotech startup wearing a 65-year-old company’s suit. And it’s actually working.
CEO Concall, February 2026: “Zaynich (WCK 5222) completed global Phase III for complicated UTI in January 2026 with superiority over meropenem. EMA awarded accelerated assessment. US FDA NDA filed October 1, 2025.” Translation: An Indian company is about to get the first approval for a novel antibiotic it invented. This has never happened before.
03 — Business Model: Pills + Pipeline
A Two-Act Play. Act 1 is Boring. Act 2 Could Be Historic.
Wockhardt’s revenue splits like this: ~80% from branded generics (existing drugs they license and manufacture), ~19% from biosimilars (anti-diabetic vertical driving 46% YoY growth), and ~1% from NCEs (the bet-the-company pipeline). Distribution spans UK (37% of FY24 revenue), India (22%), EU (13%), USA (5%, and declining post-exit), and rest-of-world (23%). It manufactures at 12 facilities across India, UK, Ireland, and Dubai. The company employs ~2,600 people and has 350+ scientists working on R&D.
Act 1 is a typical global generics play: license off-patent drugs, buy raw materials, manufacture, ship to regulated markets, collect margin. Boring, necessary, profitable-enough. Act 2 is where the bet lies: invent molecules in-house, get them approved by the USFDA, win patents that last 20 years, charge premium prices for unique therapies that treat drug-resistant infections.
The specific focus: novel antibiotics for antimicrobial resistance (AMR). A genuine unmet medical need. The WHO literally warned that AMR could kill 10 million people annually by 2050. Wockhardt’s six QIDP-approved molecules include Zaynich (cefepime + zidebactam combo) and Miqnaf (ofloxacin alternative) — both targeting resistant gram-negative infections. Miqnaf already launched in India in May 2025 and showed non-inferiority to moxifloxacin in Lancet-published trials.
Biosimilars Growth+46%YoY in H1 FY25
Patients Treated (EMROK/O)100k+Cumulative
NCE Programs (QIDP)6US FDA Approved
Manufacturing Plants124 countries
The Cost of Ambition: R&D expenditure is 3.5% of revenue in H1 FY25 (₹109 crore on ₹3,151 crore revenue). By comparison, Sun Pharma spends ~2.8%. This is not “modest R&D.” This is a bet-the-company allocation from a company still chasing profitability. If Zaynich approval takes another 3–4 years, Wockhardt burns another ₹1,500+ crore. The stock prices that risk in.
💬 Do you think an Indian biotech can compete globally in novel antibiotics, or is this a vanity project with shareholder money? Drop your view.
04 — Financials Overview
Q3 FY26: From Cliff to Inflection
Result type: Quarterly Results | Q3 FY26 EPS: ₹3.63 | Annualised EPS (Q3×4): ₹14.52 | Full-year FY25 EPS: -₹2.89
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 888 | 721 | 782 | +23.2% | +13.6% |
| Operating Profit | 177 | 128 | 178 | +38.3% | -0.6% |
| OPM % | 20% | 18% | 23% | +200 bps | -300 bps |
| PAT | 61 | 20 | 82 | +205% | -25.6% |
| EPS (₹) | 3.63 | 0.86 | 4.80 | +322% | -24.4% |
Exceptional Items Alert: Q3 FY26 includes a ₹107 crore exceptional charge, mostly ₹97 crore for US deconsolidation (exit from generics business). Strip that out, and the underlying operating profit is stronger. The company is actively de-scaling its unprofitable US operations — Chapter 7 filings for US subsidiaries concluded in Nov 2025. No more burning cash on low-margin generics in a saturated market. Focus redirected entirely to UK, Ireland, India, and emerging markets where margins exist.
05 — Valuation: Fair Value Range
Is ₹1,322 Priced For Miracles?
Join 10,000+ investors who read this every week.
